scholarly journals Letter: evaluation and proposed re‐classification of HCC prediction model in patients with chronic hepatitis C genotype 4

2021 ◽  
Vol 55 (2) ◽  
pp. 255-257
Author(s):  
Gamal Shiha ◽  
Nabiel N. H. Mikhail ◽  
Reham Soliman
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Prediction Model ◽  
Chronic Hepatitis C ◽  
Genotype 4

scholarly journals Letter: evaluation and proposed reclassification of HCC prediction model of Tahata et al. in chronic hepatitis C genotype 4 patient. Authors’ reply

2021 ◽  
Vol 55 (2) ◽  
pp. 258-259
Author(s):  
Yuki Tahata ◽  
Ryotaro Sakamori ◽  
Ryoko Yamada ◽  
Takahiro Kodama ◽  
Hayato Hikita ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Prediction Model ◽  
Chronic Hepatitis C ◽  
Genotype 4

Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4

2016 ◽  
Vol 28 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Mohamed A.S. Kohla ◽  
Hala El-Said ◽  
Ashraf El-Fert ◽  
Nermine Ehsan ◽  
Sameera Ezzat ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
Genotype 4 ◽  
Egyptian Patients

scholarly journals Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents

2010 ◽  
Vol 9 (2) ◽  
pp. 156-160 ◽  
Author(s):  
Jaber Al Ali ◽  
Salem Owayed ◽  
Wafa’a Al-Qabandi ◽  
Khaled Husain ◽  
Fuad Hasan
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Genotype 4 ◽  
Pegylated Interferon Alfa

scholarly journals An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C

PLoS ONE ◽  
2011 ◽  
Vol 6 (7) ◽  
pp. e20904 ◽  
Author(s):  
Thomas R. O'Brien ◽  
James E. Everhart ◽  
Timothy R. Morgan ◽  
Anna S. Lok ◽  
Raymond T. Chung ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Prediction Model ◽  
Chronic Hepatitis C ◽  
Il28b Genotype ◽  
Clinical Prediction ◽  
Clinical Prediction Model

scholarly journals Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Ossama Ashraf Ahmed ◽  
Eslam Safwat ◽  
Mohamed Omar Khalifa ◽  
Ahmed I. Elshafie ◽  
Mohamed Hassan Ahmed Fouad ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Adverse Events ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
World Health ◽  
Genotype 4 ◽  
Positive Results

Background and Aims. As indicated by the World Health Organization (WHO), Egypt is positioned as the country with the world’s highest prevalence of Hepatitis C virus (HCV). HCV is transmitted through unexamined blood transfusions, different employments of syringes, and poor cleansing, as per the WHO. Our study aimed at screening and management of chronic hepatitis C genotype 4 infected patients in Bardeen village, Sharkeya Governorate, Egypt, with Sofosbuvir plus Daclatasvir, as well as estimating the safety and efficacy of that regimen. Methods. Screening of adult patients in Bardeen village was done from March 2016 till November 2016 using hepatitis C virus antibodies by third-generation ELISA testing. Positive results were confirmed by PCR. Patients eligible for treatment received Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virologic response at 12 weeks following the end of treatment (SVR 12). Results. Out of 2047 subjects screened for hepatitis C virus, 249 (12.2%) showed positive results. 221 out of those 249 subjects (88.7%) had detectable RNA by PCR. Treatment of eligible patients (183 patients) with Sofosbuvir plus Daclatasvir for 12 weeks resulted in 96% achievement of sustained virologic response at week 12. Adverse events were tolerable. Conclusion. Sofosbuvir plus Daclatasvir regimen is safe and effective for treatment of chronic hepatitis C Genotype 4 infected patients with minimal adverse events. HCV eradication program implemented in Egypt can be a model for other countries with HCV and limited resources. The availability of generic drugs in Egypt will help much in eradication of the virus.

Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis

2013 ◽  
Vol 43 (12) ◽  
pp. 1255-1263 ◽  
Author(s):  
Abdulrahman A. Aljumah ◽  
Mohammad Hassan Murad
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Genotype 4 ◽  
Standard Interferon

Interferon sensitivity in chronic hepatitis C virus genotype 4 infection

2003 ◽  
Vol 38 ◽  
pp. 147-148
Author(s):  
W. Jessner ◽  
M. Gschwantler ◽  
E. Formann ◽  
P. Steindl-Munda ◽  
H. Hofmann ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virus Genotype ◽  
Genotype 4 ◽  
Chronic Hepatitis C Virus
Sign in / Sign up

Export Citation Format

Share Document